


Please type a plus sign (+) inside this box → 

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.

First Inventor or Application Identifier

Title *apparatus and method for the treatment of
Dyslipidemia using fiber-coupled lasers*

Express Mail Label No.

82195570 4278

FedEx

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)
2. ☒ Specification ☒ [Total Pages *9*]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) ☒ [Total Sheets *3*]
4. Oath or Declaration [Total Pages *1*]
- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed)
- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of Attorney (when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
11. ☐ Preliminary Amendment
12. ☐ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
13. ☒ * Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. ☐ Other: _____

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____
Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name

J. T. LIN

Address

4532 Old Carriage Trail

City

Oviedo

State

FL

Zip Code

32765

Country

Telephone

407-482-4555

Fax

407-482-0505

Name (Print/Type)

J. T. LIN

Registration No. (Attorney/Agent)

Signature

[Signature]

Date

Nov. 3, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FEE TRANSMITTAL

for FY 2000

Patent fees are subject to annual revision.
Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.
See 37 C.F.R. §§ 1.27 and 1.28.

TOTAL AMOUNT OF PAYMENT

(\$) 363.00

Complete if Known

Application Number

Filing Date

First Named Inventor

J. T. LIN

Examiner Name

Group / Art Unit

Attorney Docket No.

METHOD OF PAYMENT (check one)

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number

Deposit Account Name

☐ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17

2. ☒ Payment Enclosed:

☒ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Fee Fee Fee Fee Description

Code (\$)	Code (\$)	Code (\$)	Code (\$)	Code (\$)	Fee Description	Fee Paid
101	690	201	345		Utility filing fee	345
106	310	206	155		Design filing fee	
107	480	207	240		Plant filing fee	
108	690	208	345		Reissue filing fee	
114	150	214	75		Provisional filing fee	

SUBTOTAL (1) (\$) 345

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
22	-20** = 2	9	18
1	-3** = 0	0	0
		0	0

**or number previously paid, if greater, For Reissues, see below

Large Entity Small Entity

Fee Fee Fee Fee Fee Description

Code (\$)	Code (\$)	Code (\$)	Code (\$)	Code (\$)	Fee Description	Fee Paid
103	18	203	9		Claims in excess of 20	
102	78	202	39		Independent claims in excess of 3	
104	260	204	130		Multiple dependent claim, if not paid	
109	78	209	39		** Reissue independent claims over original patent	
110	18	210	9		** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) 18

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Fee Fee Fee

Code (\$)

Fee Description

Fee Paid

105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	380	216	190	Extension for reply within second month	
117	870	217	435	Extension for reply within third month	
118	1,360	218	680	Extension for reply within fourth month	
128	1,850	228	925	Extension for reply within fifth month	
119	300	219	150	Notice of Appeal	
120	300	220	150	Filing a brief in support of an appeal	
121	260	221	130	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,210	241	605	Petition to revive - unintentional	
142	1,210	242	605	Utility issue fee (or reissue)	
143	430	243	215	Design issue fee	
144	580	244	290	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	690	246	345	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	690	249	345	For each additional invention to be examined (37 CFR § 1.129(b))	

Other fee (specify)

Other fee (specify)

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type)

J. T. LIN

Registration No.
(Attorney/Agent)

Complete (if applicable)

Telephone

407-482-4555

Signature

[Signature]

Date

NOV. 3, 2000

WARNING:

Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))—INDEPENDENT INVENTOR**

Docket Number (Optional)

Applicant, Patentee, or Identifier: J. T. LIN

Application or Patent No.: _____

Filed or Issued: _____

Title: Apparatus & methods for the Treatment of
Myopia using fiber-coupled Lasers

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.
☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

J. T. LIN
NAME OF INVENTOR

[Signature]
Signature of inventor

Nov. 3, 2000
Date

NAME OF INVENTOR

Signature of inventor

Date

NAME OF INVENTOR

Signature of inventor

Date

APPARATUS AND METHODS FOR THE TREATMENT OF PRESBYOPIA USING FIBER-COUPLED-LASERS

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to methods and apparatus for the treatment of presbyopia using fiber-coupled lasers to ablate the sclera tissue.

2. Prior Art

Corneal reshaping including a procedure called photorefractive keratectomy (PRK) and a new procedure called laser assisted in situ keratomileusis, or laser intrastroma keratomileusis (LASIK) have been performed by lasers in the ultraviolet (UV) wavelength of (193 - 213) nm. The commercial UV refractive lasers include ArF excimer laser (at 193 nm) and other non-excimer, solid-state lasers such as those proposed by the present inventor in 1992 (US pat. no. 5,144,630) and in 1996 (US pat. No. 5,520,679). The above-described prior arts using lasers to reshape the corneal surface curvature, however, are limited to the corrections of myopia, hyperopia and astigmatism..

Refractive surgery using a scanning device and lasers in the mid-infrared (mid-IR) wavelength was first proposed by the present inventor in US Pat. No. 5,144,630 and 5,520,679 and later proposed by Telfair et. al., in US Pat. No. 5,782,822, where the generation of mid-IR wavelength of (2.5-3.2) microns were disclosed by various methods including: the Er:YAG laser (at 2.94 microns), the Raman-shifted solid state lasers (at 2.7-3.2 microns) and the optical parametric oscillation (OPO) lasers (at 2.7-3.2 microns).

Corneal reshaping may also be performed by laser thermal coagulation currently conducted by a Ho:YAG laser (at about 2 microns in wavelength) proposed by Sand in US Pat. 5,484,432. This method, however, was limited to low-diopter hyperopic corrections. Strictly speaking this prior art did not correction the true "presbyopia" and only performed the mono-vision for hyperopic patients. A thermal laser is required and the laser treated area was within the optical zone diameters of about 7 mm.

Ruiz in US pat. No. 5,533,997 proposed the use of laser ablation of cornea surface to correct presbyopic patients. This prior art, however, must generate multifocal (or bifocal) surface on the central portion of the cornea in order to achieve the desired presbyopia correction. Corneal curvature change by laser ablation in this prior art, however, did not

1 actually resolve the intrinsic problems of presbyopic patient caused by age where the cornea
2 lens loss its accommodation as a result of loss of elasticity due to age.

3 All the above-described prior arts are using methods to change the cornea surface
4 curvature either by tissue ablation (such as in UV laser) or by thermal shrinkage (such as in
5 Ho:YAG laser) and all are using lasers onto the central portion of the cornea.

6 The alternative method for presbyopia correction, therefore, is to increase the
7 accommodation of the presbyopic patients by change the intrinsic properties of the sclera and
8 ciliary tissue to increase the lens accommodation without changing the cornea curvature. This
9 method of sclera ablation is fundamentally different from all the prior arts including that of
10 Ruiz, in which reshaping cornea curvature into multifocal shape was required for presbyopia
11 correction.

12 Correction of presbyopia via the expanding of the sclera by mechanical devices was
13 recently proposed by Schachar in US patents 5,489,299 and 5,354,331. These prior arts all
14 require the implant of external band or using laser heating to affect the position of the
15 insertion band and have the drawbacks of complexity, time consuming, costly and potential
16 for side effects. To treat presbyopia, Schachar's other US patents 5,529,076 and 5,722,952,
17 proposed the use of heat or radiation on the corneal epithelium to arrest the growth of the
18 crystalline lens by laser coagulation effects. However these two prior arts did not present any
19 details or practical methods and there was no clinical studies have been practiced to show the
20 effectiveness of the proposed concepts.

21 Roberto Albertazzi et al (Ocular Surgery News, July, 1999) recently proposed to use
22 diamond knife for the incision of the sclera tissue outside the limbus rings to increase the
23 space for sclera expansion. This method however caused corneal bleeding and regression is
24 frequently found after the treatments. We note that there is intrinsic difference between a laser
25 ablation proposed in this invention and the knife incision. The sclera space produced by the
26 incision method is not permanent and may be greatly reduced during the tissue healing and
27 cause the regression. This major source of regression in incision method however will not
28 occur in the laser ablation method as proposed in this invention, where portion of the sclera
29 tissue is permanently removed.

30 The "presbyopia" correction proposed by Ruitz (US Pat. No. 5,533,997) using an
31 excimer (ArF) laser also required the corneal surface to be reshaped to form "multifocal"
32 effort for a presbyopia patients to see near and far. However, Ruitz's "presbyopia" correction is
33 fundamentally different from that of the present patent which does not change the corneal
34 curvature. The presbyopia correction proposed in the present patent is to increase patient's

1 accommodation rather than reshaping the cornea into "multifocal" surface.

2 The technique used in the prior art of Bille (Pat. No. 4,907,586) required a quasi-
3 continuous laser having pulse duration less than 10 picoseconds and focused spot less than 10
4 micron diameter and the laser is confined to the interior of a selected tissue to correct myopia,
5 hyperopia or astigmatism. Bille also proposed the laser to focused into the lens of an eye to
6 prevent presbyopia. This prior art system is very complicate and needs a precise control of the
7 laser beam size and focusing position. Furthermore, clinical risk of cataract may occur when
8 laser is applied into the lens area.

9 Treatment of presbyopia by cold lasers was recently proposed by the present inventor in
10 US Pat. Application Nos. 09/189,609 and 09/391,503. These pending patents, however,
11 require the use of a scanning device to generate the laser ablation patterns on the cornea.
12 These systems therefore involve with complicated hardware and software for scanning
13 patterns and patient centration or eye movement is critical.

14 Accordingly, there is a strong need to treat presbyopia via laser ablation of the sclera
15 tissue using a laser system which may be delivered by a hand held fiber unit. Furthermore,
16 the system may be used in either non-contact or contact modes with laser beam spot sizes
17 defined by the size and shapes of the fiber tips. System proposed in the present patent will be
18 safer than that of prior arts because the central portion of the cornea remains intact and only
19 the area outside the limbus will be ablated by the laser. It is yet another objective of the
20 present patent is to provide a no-invasive method where the conjunctiva layer may be lifted to
21 generate the "gap" for fiber tip to insert into the gap and ablate the desired patterns underneath
22 and to avoid or minimize bleeding or infection.

23 24 SUMMARY OF THE INVENTION

25 The preferred embodiments of the basic surgical lasers of the present
26 invention shall include: (a) infrared (IR) lasers having wavelengths range of about (1.4 – 3.2)
27 microns including but not limited to solid state lasers of Er:glass, Ho:YAG, Er:YAG,
28 Er:YSGG, infrared gas lasers, solid-state lasers converted by optical parametric oscillation
29 (OPO); (b) ultraviolet (UV) lasers having wavelength range of about (190 – 355) nm, such as
30 ArF (at 193 nm) and XeCl (at 308 nm) excimer lasers and solid-state lasers using frequency
31 conversions; (c) semiconductor diode lasers at about 980 nm, (1.3-1.55) microns, and (1.8-
32 2.1) microns; (d) diode-pumped solid state lasers having wavelength range of about (190-355)
33 nm and (2.7-3.2) microns such as diode-pumped Er:YSGG, Er:YAG, Nd:YAG, Er:glass and
34 Ti:sapphire laser and their harmonic generation.

1 It is yet another preferred embodiment is to couple the basic lasers by a fiber
2 and deliver the laser beam to the treated area of the eye by a handheld piece which is further
3 connected to a fiber-tip at various shapes.

4 It is yet another preferred embodiment to focus the laser beams into a desired
5 spot size on the treated area of the eye. Various ablation patterns may be generated manually
6 via the fiber-connected hand piece including multiple rings of spots and radial line incisions
7 outside the limbus.

8 It is yet another preferred embodiment is to open the conjunctiva layer prior to
9 the laser ablation of the under-layer of the sclera tissue for a better control of the ablation
10 depth and for safety reasons. It is yet another preferred embodiment is that the conjunctiva
11 layer may be lifted to generate the "gap" for fiber tip to insert into the gap and ablate the
12 desired patterns underneath and to avoid or minimize bleeding or infection.

13 Further preferred embodiments of the present invention will become apparent
14 from the description of the invention which follows.

15 16 **BRIEF DESCRIPTION OF THE DRAWINGS**

17 FIG. 1 is a block diagram of the integrated laser system consisting of a laser, a
18 coupling fiber delivery unit and a hand-piece connected to a fiber-tip to control the beam spot
19 on the treated area.

20 FIG. 2 shows various shapes of the fiber tips: (A) flat tip, (B) spherical tip for focused
21 contact use, (C) conical tip, (D) 90-degree angle tip, and (E) focused slit-spot.

22 FIG. 3 shows various ablation patterns generated by the ablating laser outside the
23 limbus.

24 25 **DETAILED DESCRIPTION OF THE INVENTION AND THE** 26 **PREFERRED EMBODIMENTS** 27

28 Referring to Fig. 1, a surgical laser system in accordance with the present invention
29 comprises a basic laser 1 having wavelength 2 coupled by a focusing lens 3 to a fiber 4 which
30 is connected to a hand-piece 5 and a fiber tip 6. The focusing lens 3, fiber 4 and fiber tip 6 are
31 highly transparent to the wavelength 2 of the basic laser.

32 Still referring to Fig. 1, according to the present invention, the preferred
33 embodiments of the basic surgical lasers for presbyopia correction procedures shall include:
34 (a) infrared lasers having wavelengths range of about (1.4 – 3.2) microns including but not

1 limited to solid state lasers of Er:glass, Ho:YAG, Er:YAG, Er:YSGG, infrared gas lasers,
2 solid-state lasers converted by optical parametric oscillation (OPO); (b) ultraviolet (UV)
3 lasers having wavelength range of about (190 – 355) nm, such as ArF (at 193 nm) and XeCl
4 (at 308 nm) excimer lasers and solid-state lasers using harmonic generation from solid-state
5 lasers of Nd:YAG, Nd:YLF and Alexandrite lasers frequency conversions; (c) semiconductor
6 diode lasers at about 980 nm, (1.3-1.55) microns, and (1.8-2.1) microns; (d) diode-pumped
7 solid state lasers having wavelength range of about (190-355) nm and (2.7-3.2) microns such
8 as diode-pumped Er:YSGG, Er:YAG, Nd:YAG and Er:glass. and; (e) diode lasers having
9 wavelength at about 980 nm, 1.5 microns, and 1.9 microns.

10 According to one aspect of the present invention, the preferable scanning laser energy per
11 pulse on corneal surface is about (2-20) mJ in IR lasers and about (0.5 – 2.0) mJ in UV lasers.
12 Focused spot size of about (0.1-0.5) mm in diameter on the corneal plane is achieved by the
13 focusing lens 3 which consists of at least one spherical lens. The other preferred laser
14 parameter of this invention is the laser repetition rate range of about (5-100) Hz which will
15 provide reasonable surgical speed and minimum thermal effects. The focused beam may be
16 scanned over the corneal surface to ablate various patterns to achieve the desired sclera
17 expansion.

18 Referring to Fig. 2(A), the laser output from the fiber end having wavelength 2 is
19 connected to the hand-piece 5 and a flat fiber tip 6 such that the output laser beam from the
20 end of the fiber tip is a round-beam with a pre-determined spot size of about (0.1-0.5) mm.
21 Fig. 2(B) shows similar structure to Fig. 2(A), except the output round-spot beam is re-
22 focused by the spherical shape of the tip. Fig. 3 (C) shows the output beam 2 is guided by a
23 conical shape tip such that the beam size at the end of the tip is reduced. Fig. 2(D) shows that
24 the output beam is reflected by 90-degree by a coated fiber tip. Finally Fig. 2(E) shows an
25 output beam spot is a slit-shape having a size of about (0.1-0.5) x (1.5-3.0) mm formed by a
26 cylinder lens attached to the end of the fiber tip.

27 Fig. 3 shows an eye 7 of a presbyopic patient with ablation patterns 9 generated on the
28 scleral area about (0.5-1.0) mm posterior to the corneal limbus 8. The preferred patterns of
29 this invention include a ring-spot having at least one ring with at least 3 spots in each ring,
30 and a radial-pattern having at least 3 radials. The preferred area of the ablation is defined
31 within two circles having diameters about 10 mm and 14 mm posterior to the limbus along
32 the radial direction of the cornea. We should note that a radial ablation pattern on the corneal
33 surface may be generated either by an automatic scanning device or by manually scan the
34 fiber tip by a surgeon who hold the hand piece. For the situation of the slit fiber-tip, the

1 surgeon may easily generate the radial patterns without moving the tip.

2 The ablation depth of the sclera ciliary tissue is about (400-700) microns with each of the
3 radial length of about (2.5 - 4.0) mm adjustable according to the optimal clinical outcomes
4 including minimum regression and maximum accommodation for the presbyopic patients.
5 The preferred radial ablation shall start at a distance about (4.0 – 5.5) mm from the corneal
6 center and extended about (2.0-4.0) mm outside the limbus. The preferred embodiments of the
7 radial patterns on the sclera area include at least 3 radial lines or ring-dots in a symmetric
8 geometry as shown in Fig. 3.

9 Still referring to Fig. 3, the preferred embodiments to generate the radial patterns on the
10 sclera area include the following examples. (A) Scan the round laser spot of about (0.2- 0.5)
11 mm in diameter produced from the fiber tips in the radial directions to generate each of the
12 radial lines. Generation of the radial patterns may be done either manually moving the fiber
13 tip along the cornea radial direction or by an automatically a scanner or translator. (B) Use a
14 focused slit-beam to generate the radial lines. In case (B), a scanning device is not needed and
15 each of the radial lines may be generated by the slit beam directly.

16 One preferred embodiment is to coagulate the conjunctiva layer and then cut (by a knife)
17 a half-circle over the conjunctiva surrounding the limbus with a diameter about 10 mm which
18 is then pushed aside in order for the ablating laser to cut the sclera layer underneath. It is also
19 possible to use the ablating laser to cut the conjunctiva layer which however may take a
20 longer time than cutting by a knife. Another preferred embodiment is not to open the
21 conjunctiva layer, but to insert the fiber tip through the conjunctiva layer and ablate the sclera
22 tissue underneath such that the procedure is done non-invasively. To do this procedure, the
23 conjunctiva layer may be lifted to generate the “gap” for fiber tip to insert into the gap and
24 ablate the desired patterns underneath. Additional advantages of this invasive method is to
25 avoid or minimize bleeding or infection. We note that most of the bleeding is due to cutting of
26 the conjunctiva tissue rather than the laser ablation of the sclera tissue.

27 While the invention has been shown and described with reference to the preferred
28 embodiments thereof, it will be understood by those skilled in the art that the foregoing and
29 other changes and variations in form and detail may be made therein without departing from
30 the spirit, scope and teaching of the invention. Accordingly, threshold and apparatus, the
31 ophthalmic applications herein disclosed are to be considered merely as illustrative and the
32 invention is to be limited only as set forth in the claims.

CLAIMS:

I claim:

1. A system, adaptable for performing presbyopic correction in which a portion of the corneal sclera tissue is removed by steps of:

(a) selecting a laser beam having a predetermined wavelength;

(b) selecting a beam spot controller mechanism, said beam spot controller to reduce and focus said laser beam to a fiber delivery unit;

(c) controlling the said fiber delivery unit to deliver said laser beam in a said predetermined pattern onto a plurality of positions on the corneal surface to remove portion of the sclera tissue outside the limbus area, whereby a presbyopic patient's vision is corrected to see near and far by increasing the accommodation of the lens.

2. A system as claimed in claim 1, wherein said laser beam is an ultraviolet laser having a wavelength range of about (0.15 - 0.36) microns and a pulse duration less than about 200 nanoseconds.

3. A system as claimed in claim 1, wherein said laser beam is an infrared laser having a wavelength range of about (1.4 - 3.2) microns.

4. A system as claimed in claim 2, wherein infrared laser is an optically pumped Erbium:YAG laser having a wavelength of about 2.9 microns.

5. A system as claimed in claim 1, wherein said laser beam is an ArF excimer laser having a wavelength of 193 nm.

6. A system as claimed in claim 1, wherein said laser beam is a XeCl excimer laser having a wavelength of 308 nm.

7. A system as claimed in claim 1, wherein said laser beam is a solid state diode laser having a wavelength range of about (0.95 - 2.1) microns.

8. A system as claimed in claim 1, in which said beam spot controller consists of at least one focusing spherical lens to couple the said laser beam to the said fiber delivery unit.

9. A system as claimed in claim 1, wherein said fiber delivery unit consists of an optical fiber having a length of about (0.5 - 1.5) meter and core diameter of about (0.2 - 0.8) mm and a hand piece connected to a fiber tip.

1 10. The apparatus of claim 9, wherein said fiber delivery unit is substantially
2 transparent to the wavelength of the said laser beam.

3 11. The apparatus of claim 9, wherein said fiber tip is made of a similar material as
4 that of the fiber and is made in one of the following shapes to focus the said laser beam onto
5 the treated sclera area of the eye: conical, spherical, 90-degree reflecting angle and flat end.

6 12. The apparatus of claim 9, wherein said fiber tip focuses the said laser beam onto
7 the treated area of the eye at a spot size of about (0.1 - 0.5) mm in diameter.

8 13. The apparatus of claim 9, wherein said fiber tip is made in a cylinder shape to
9 focus the said laser beam onto the treated area of the eye at a line shape having a dimension of
10 about (0.1 - 0.4) in width and (0.5 - 4.0) mm in length.

11 14. The apparatus of claim 9, wherein said fiber tip is operated in a contact-mode to
12 ablate the sclera tissue to a depth of about (300 - 800) microns.

13 15. The apparatus of claim 9, wherein said fiber tip is operated in a non-contact mode
14 to ablate the sclera tissue to a depth of about (300 - 800) microns.

15 16. The apparatus of claim 1, wherein said fiber delivery unit is controlled by the
16 surgeon to perform a predetermined patterns outside the limbus of the cornea by manually
17 moving the fiber tip in the radial direction of the cornea.

18 17. A system as claimed in claim 1, wherein said fiber delivery unit is attached to a
19 scanning device to perform said predetermined patterns outside the limbus of the cornea and
20 scan said laser beam along the radial direction of the cornea.

21 18. A system as claimed in claim 1, wherein said predetermined patterns outside the
22 limbus of the cornea defined by the area between two circles having radius of about 5.0 mm
23 and 9.0 mm, respectively.

24 19. A system as claimed in claim 1, wherein said predetermined pattern includes at
25 least 3 radial lines around the area outside the corneal limbus.

26 20. A system as claimed in claim 1, wherein said predetermined pattern includes at
27 least two rings formed by 8 circular spots having a diameter of about (0.2 - 0.5) mm around
28 the area outside the corneal limbus.

29 21. A system as claimed in claim 1, wherein said sclera tissue is removed by said
30 laser beam after the cornea conjunctiva is open.

31 22. A system as claimed in claim 1, wherein said sclera tissue is removed by said
32 laser beam without opening the cornea conjunctiva.

ABSTRACT

Systems and surgical techniques for presbyopia correction by laser removal of the sclera tissue are disclosed. The disclosed preferred embodiments of the system consists of a beam spot controller, a fiber delivery unit and a fiber tip. The basic laser including UV lasers and infrared lasers having wavelength ranges of (0.15-0.36) microns and (1.9-3.2) microns and diode lasers of about 0.98, 1.5 and 1.9 microns. Presbyopia is treated by a system which uses an ablative laser to ablate the sclera tissue outside the limbus to increase the accommodation of the ciliary body of the eye. The sclera tissue may be ablated by the laser with or without the conjunctiva layer open.

J. T. Lin
FIG. 1




FIG. 1






FIG. 2




(A)



(B)

FIG. 3

Please type a plus sign (+) inside this box → 

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☒ Declaration
Submitted
with Initial
Filing

OR

☐ Declaration
Submitted after Initial
Filing (surcharge
(37 CFR 1.16 (e))
required)

Attorney Docket Number

First Named Inventor

J. T. KIN

COMPLETE IF KNOWN

Application Number

/

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

*Apparatus & method for the Treatment of Presbyopia
using fiber coupled-lasers.*

the specification of which

(Title of the Invention)

☒ is attached hereto
OR

☐ was filed on (MM/DD/YYYY)

as United States Application Number or PCT International

Application Number

and was amended on (MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☐ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here

Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label

OR ☒ Correspondence address below

Name	J. T. LIN				
Address	4532 Old Carriage Trail				
Address					
City	Oviedo	State	FL	ZIP	32765
Country		Telephone	407-482-4555	Fax	407-482-0505

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname					
J. T.		LIN					
Inventor's Signature				Date	11/3/00		
Residence: City	Oviedo	State	FL	Country	USA	Citizenship	USA
Post Office Address	4532 Old Carriage Trail						
Post Office Address							
City	Oviedo	State	FL	ZIP	32765	Country	USA

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto